首页
>
>
投稿咨询
微信添加科研助理

了解相关问题

加急服务
微信添加科研助理

了解相关问题

PHARMACOGENOMICS
ISSN：1462-2416

PHARMACOGENOMICS

PHARMACOGENOMICS
学科领域：医学
是否预警：不在预警名单内
是否OA：否
录用周期：偏慢,4-8周
新锐分区：医学4区
年发文量：51
影响因子：1.9
JCR分区：Q3

基本信息

药物基因组学（ISSN 1462-2416）是一本同行评审期刊，由密切参与这一快速发展领域的研究人员和决策者提供评论和报告。主要目标是为社会提供一个重要的资源，以保持在这个令人兴奋的领域的所有领域的最新发展。药物基因组学是评论和分析的主要来源，为您带来来自该领域企业和学术意见领袖的最高质量的专家分析。
1462-2416SCIE/Scopus收录
1.9
点击查看最新影响趋势>
1.5
新
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学4区
PHARMACOLOGY & PHARMACY 药学
4区
否
N/A
新
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科：PHARMACOLOGY & PHARMACY
SCIE
Q3
238/352
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科：PHARMACOLOGY & PHARMACY
SCIE
Q3
256/353
83
51
点击查看年发文量趋势图>
10%0偏慢,4-8周-医学-药学
5.3%
点击查看自引率趋势图>
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
78.43%12.56%0.93%
CiteScore：3.30
SJR：0.516
SNIP：0.505
学科类别分区排名百分位
大类：Pharmacology, Toxicology and Pharmaceutics
小类：Pharmacology
Q3
197 / 321
大类：Pharmacology, Toxicology and Pharmaceutics
小类：Genetics
Q3
235 / 348
大类：Pharmacology, Toxicology and Pharmaceutics
小类：Molecular Medicine
Q3
132 / 177

期刊高被引文献

Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0166
A systematic review of genome-wide association studies of antipsychotic response.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0163
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0149
Pharmacogenetic testing in primary care practice: opinions of physicians, pharmacists and patients.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0004
Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0009
Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0144
Pharmacogenomics courses in pharmacy school curricula.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0024
Systems pharmacogenomics - gene, disease, drug and placebo interactions: a case study in COMT.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0001
Polymorphisms in IGF2/H19 gene locus are associated with platinum-based chemotherapeutic response in Chinese patients with epithelial ovarian cancer.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0153
Implementation of wide-scale pharmacogenetic testing in primary care.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0043
CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0143
A stepwise approach to implementing pharmacogenetic testing in the primary care setting.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0053
Implementing pharmacogenetic testing in rural primary care practices: a pilot feasibility study.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0200
GLP1R variant is associated with response to exenatide in overweight Chinese Type 2 diabetes patients.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0159
Methotrexate pharmacogenetics in the treatment of rheumatoid arthritis.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0121
Association between genetic polymorphisms and angiotensin-converting enzyme inhibitor-induced cough: a systematic review and meta-analysis.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0157
The impact of CYP2C19 and CYP4F2 variants and clinical factors on treatment outcomes during antiplatelet therapy.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0178
APOE polymorphism is associated with blood lipid and serum uric acid metabolism in hypertension or coronary heart disease in a Chinese population.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0048
Perplexed by PGx? Exploring the impact of pharmacogenomic results on medical management, disclosures and patient behavior.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0179
Characterizing the pharmacogenome using molecular inversion probes for targeted next-generation sequencing.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0057
The future of pharmacogenetics in the treatment of hypertension.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0191
Integrated CYP2D6 interrogation for multiethnic copy number and tandem allele detection.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0135
Pharmacomicrobiomics informs clinical pharmacogenomics.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0027
GWAS contribution to atrial fibrillation and atrial fibrillation-related stroke: pathophysiological implications.
来源期刊：PharmacogenomicsDOI：10.2217/PGS-2019-0054
DEPTOR polymorphisms influence late complications in Type 2 diabetes patients.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0058
Identification of a single-nucleotide polymorphism within CDH2 gene associated with bone morbidity in childhood acute lymphoblastic leukemia survivors.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0169
Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplant.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0002
Pharmacogenomics in the Nigerian population: the past, the present and the future.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0046
Evaluation of the predictive performance of Bayesian dosing for warfarin in Chinese patients.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0127
High levels of several antipsychotics and antidepressants due to a pharmacogenetic cause: a case report.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0037
CYP2C19 genotype, physician prescribing pattern, and risk for long QT on serotonin selective reuptake inhibitors.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0156
CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinoma.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0094
Letter to the editor: reply to Bousman et al.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0110
Implementation of pharmacogenetics in a clozapine treatment resistant patient: a case report.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0074
Association between SLCO1B1 rs4149056 and tegafur-uracil-induced hepatic dysfunction in breast cancer.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0100
Influence of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0196
Activation of HCAR2 by niacin: benefits beyond lipid lowering.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0092
NR3C1, ABCB1, TNF and CYP2C19 polymorphisms association with the response to the treatment of erythema nodosum leprosum.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0192
Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0101
Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0139
The GNAS SNP c.393C>T (rs7121) as a marker for disease progression and survival in cancer.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0199
Bayesian modeling to predict malignant hyperthermia susceptibility and pathogenicity of RYR1, CACNA1S and STAC3 variants.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0055
Early adoption of pharmacogenetic testing for veterans prescribed psychotropic medications.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0065
The ANKS1B gene and its associated phenotypes: focus on CNS drug response.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0015
NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0131
Resequencing CYP2D6 gene in Indian population: CYP2D6*41 identified as the major reduced function allele.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0049
The effects of rosiglitazone on the neonatal rat cardiomyocyte transcriptome: a temporal analysis.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0077
A potential role for the CDH13/CDH15 gene in repeat revascularization after first percutaneous coronary intervention.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2019-0118
Genetic variation of kinases and activation of nucleotide analog reverse transcriptase inhibitor tenofovir.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0140
Impact of genetic polymorphisms on opioid misuse: a scoping review.
来源期刊：PharmacogenomicsDOI：10.2217/pgs-2018-0180

相关文章

Materials Today Bio解析：IF=8.7，8天初审
2025-11-25
《ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE》德国老牌产科期刊免版面费、非预警，毕业保底首选！
2025-11-25
Journal of Multidisciplinary Healthcare：IF= 2.4，中科院3区，JCR Q2，多学科综合医学开放获取期刊，应用性强，审稿迅速，编辑反馈专业！
2025-10-15
European Journal of Medical Genetics：IF= 1.7，中科院4区，JCR Q3，医学遗传学期刊，涵盖分子遗传学、临床基因诊断与罕见病研究，欧洲地区影响力较稳，国际传播适中！
2025-10-15
ANNALS OF ONCOLOGY：中科院1区，肿瘤学，接受率为25%
2025-10-15
Journal of Cystic Fibrosis：权威官方背景，高影响力，整体周期约 3 个月，部分 1 天录用
2025-10-15
JOURNAL OF INHERITED METABOLIC DISEASE：影响因子平稳，学术认可度高，年发文稳定，4个月录用
2025-10-15
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE：自引风险小，审稿周期短，发表难度低，但if持续下降
2025-10-15
Neurobiology of Stress：中科院 2 区，认可度高，国人发文第二，机会公平
2025-10-15
NATURE REVIEWS DRUG DISCOVERY：中科院1区，生物工程与应用微生物，药学，接受率为21%
2025-10-15

期刊推荐

ACSMS HEALTH & FITNESS JOURNAL封面

ACSMS HEALTH & FITNESS JOURNAL

学科领域：医学
影响因子：1.8
中科院分区： 4区
ACTA BIOQUIMICA CLINICA LATINOAMERICANA封面

ACTA BIOQUIMICA CLINICA LATINOAMERICANA

学科领域：医学
影响因子：0.1
中科院分区： 4区
Acta Cardiologica Sinica封面

Acta Cardiologica Sinica

学科领域：医学
影响因子：1.8
中科院分区： 4区
Acta Chirurgiae Orthopaedicae et Traumatologiae Cechoslovaca封面

Acta Chirurgiae Orthopaedicae et Traumatologiae Cechoslovaca

学科领域：医学
影响因子：0.4
中科院分区： 4区
论文发表 2-4个月录用 7500+文章录用 不成功可退款
新
2026年3月发布
大类学科小类学科Top期刊综述期刊
医学4区
PHARMACOLOGY & PHARMACY 药学
4区
否
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学4区
PHARMACOLOGY & PHARMACY 药学
4区
否
否
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学4区
PHARMACOLOGY & PHARMACY 药学
4区
否
否